Navigation Links
FDA Approves GlaxoSmithKline's AVODART(R) in Combination with Tamsulosin for the Treatment of Symptomatic Enlarged Prostate
Date:6/19/2008

PHILADELPHIA, June 19 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: GSK) today announced that the U.S. Food and Drug Administration (FDA) has approved AVODART (dutasteride) in combination with tamsulosin for the treatment of symptomatic enlarged prostate, a disease that affects half of all men over 50 years old. The new indication reflects emerging research showing the combination of the two medicines treats the symptoms of enlarged prostate more effectively than either medicine alone.

"The combination of AVODART and tamsulosin at diagnosis allows doctors to simultaneously treat the patient's prostate on two fronts by reducing prostate size and rapidly improving symptoms," said Steven A. Kaplan, M.D., from Weill Cornell Medical College of Cornell University in New York City.

Common symptoms of enlarged prostate include nocturia, frequent and urgent urination, incomplete emptying, starting and stopping, and weak stream. If left untreated, enlarged prostate can lead to hospitalization for the inability to urinate or prostate surgery.

AVODART already had been approved by the FDA for the treatment of enlarged prostate to improve urinary symptoms, reduce the risk of acute urinary retention (AUR), and reduce the risk of prostate-related surgery. Tamsulosin, an alpha-blocker, already had been indicated for the treatment of the signs and symptoms of enlarged prostate.

The FDA approval was based on two-year results of the CombAT (Combination of Avodart and Tamsulosin) study, one of the largest clinical trials to date of men with enlarged prostate. The CombAT study is the first long-term assessment of the combination of AVODART and an alpha-blocker. Study results were first presented in September 2007 at the 29th annual meeting of the Societe Internationale d'Urologie in Paris. The study was published in the February issue of the Journal of Urology.

The CombAT study results showed that combination therapy with AVODART and tamsulosi
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Arpida Annual General Meeting of Shareholders Approves All Board Proposals
2. FDA Approves MIXJECT(TM), a Convenient, Easy-to-Use Drug Delivery System For Watson Pharmaceuticals TRELSTAR(R) DEPOT and TRELSTAR(R) LA
3. FDA Approves VYVANSE(TM) (lisdexamfetamine dimesylate), the First and Only Once-Daily Prodrug Stimulant to Treat ADHD in Adults
4. Maryland Approves Medicaid Reimbursement for ActiPatch(R)
5. Healthcare Coalition Approves Tools to Improve Patient Safety During Transitions of Care
6. Medicare Approves in Home Sleep Apnea Testing
7. 3SBio Inc. Approves Share Repurchase Program
8. Baxters Board of Directors Approves New Share Repurchase Authorization of $2 Billion
9. FDA Approves PRISTIQ(TM) for the Treatment of Adult Patients with Major Depressive Disorder
10. FDA Approves INTELENCE(TM) (etravirine) for HIV Combination Therapy
11. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... 2015 /PRNewswire/ - Aptose Biosciences Inc. (NASDAQ: APTO, TSX: ... diagnostics that target the underlying mechanisms of cancer, today ... ended December 31, 2014. Effective July 17, ... May 31 to December 31. As a result of ... for the quarter and the seven months ended December ...
(Date:3/3/2015)... 3, 2015  Halozyme Therapeutics, Inc. (NASDAQ: HALO ... Conference in Miami, FL on March ... A. Ramsay , Chief Financial Officer, will provide a corporate ... "Investors" section of Halozyme,s corporate website at www.halozyme.com , ... following the event. To access the live webcast, please log ...
(Date:3/3/2015)... NASA astronaut Scott Kelly , who is ... a year living and working on the International Space Station, ... 7 a.m. EDT Monday, March 9. Kelly will ... the final weeks of his training. The interviews will be ... highlighting his mission training and previous spaceflights. To ...
(Date:3/3/2015)... March 03, 2015 Experts and industry ... for one event: the Alltech REBELation exploring innovation, inspiration ... 17-20. Now in its 31st year, Alltech’s annual international ... countries, and the opportunity to join the REBELation at ... at 11:59 p.m. EST, at which point the standard ...
Breaking Biology Technology:Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 2Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 3Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 4Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 5Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 6Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 7Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 8Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 9Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 10Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 11Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 12Halozyme Therapeutics To Present At The Barclays 2015 Global Healthcare Conference 2NASA Astronaut Scott Kelly Available for Interviews before One-Year Space Station Mission 2World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 2World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 3World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 4
... (NASDAQ: HALO ) will be presenting at the ... th Annual Roth Conference in Dana Point on March ... Chief Financial Officer of Halozyme Therapeutics, will provide a corporate ... Miami on March 14, 2012 at 4:15 p.m. ET/1:15 p.m. ...
... NEW YORK, March 7, 2012 Medtrack One View, a ... for the life science industry will be available for demonstration ... of the show will be among the first to view ... View solution gives clients the ability to identify in- and ...
... leaders from across California,s life sciences industry will converge ... by Patients on March 8-9. The conference focus is ... and collaborative research. For the first time, ... California,s life sciences companies. CALBIO2012: Driven by Patients will ...
Cached Biology Technology:Halozyme Therapeutics to Present at Two Upcoming Investor Conferences in March 2Be One of the First to Experience Medtrack One View at the AUTM 2012 Annual Meeting 2First Statewide Biotech Meeting Focuses on Patient Access, Innovation 2
(Date:3/3/2015)... LAKE FOREST, Calif. , March 3, ... ("Company"), the leading provider of advanced cryogenic ... serving markets including immunotherapies, stem cells, cell ... health, and reproductive medicine, today announced the ... Hutchinson Cancer Research Centers, ("Fred Hutch") ...
(Date:3/2/2015)... Calif. , March 2, 2015 ... leading developer of human interface solutions, today announced ... that is designed to enable rapid and secure ... ID™ module for gaming is a turnkey solution ... the ability to quickly integrate fingerprint ID solutions ...
(Date:3/2/2015)...  Businesses have a new option for premier ... Enterprises has announced the launch of a brand ... businesses to protect their customers, personal data, as ... Beconux is a biometric transaction processing system recently ... an ATM machine, the new system fuses multiple ...
Breaking Biology News(10 mins):Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 2Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 3Synaptics Unveils New Fingerprint ID Solution for Gamers 2Synaptics Unveils New Fingerprint ID Solution for Gamers 3Personal Data Protection Company Launches New Product 2
... structure of a retrovirus enzyme whose configuration had stumped ... achieved their discovery by playing Foldit, an online game ... the structure of protein molecules. After scientists repeatedly ... enzyme from an AIDS-like virus, they called in the ...
... study of the effects of rapidly rising temperatures in the ... stocks is already well underway. But it isn,t all bad ... Biology , shows that some fishes, losses are other fishes, ... the University of Bristol in collaboration with researchers from eight ...
... MADISON, WI, SEPTMEBER 12, 2011 -- Modifying soybean ... and reduce feed costs and nutrient pollution. However, further ... of soybean and other crops such as maize suggest ... in plant tissue, in seeds reduces seed germination and ...
Cached Biology News:Gamers succeed where scientists fail 2Gamers succeed where scientists fail 3Some like it hot -- European fish stocks changing with warming seas 2Breeding soybeans for improved feed 2
Cell Culture Flask, nontreated polystyrene...
... CellBIND surface is produced by a ... more hydrophilic surface giving more consistent, ... and yields. CellBIND enhances cell attachment ... reduced serum or serum-free medium. • ...
... system, 100-240 V, uses xMAP technology for ... proteins and peptides in one microplate well. ... to 100 color-coded bead sets, each of ... reactant (enzyme substrates, receptors, antigens, or antibodies) ...
... (HTF) system, 100-240 V, is an optional ... that automates delivery of up to 20 ... array reader. The HTF system automatically draws ... container to constantly maintain a reservoir of ...
Biology Products: